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Summary
While T cells respond directly to toll-like receptor
(TLR) agonists, TLR-signaling pathways in T cells
are poorly characterized. Here we demonstrate in
CD4+ T cells that CpG DNA directly enhances prolifer-
ation, prevents anergy, and augments humoral re-
sponses to a T cell-dependent antigen by a Myeloid
differentiation primary-response protein 88 (MyD88)
and Phosphatidylinositol 3-kinase (PI-3 kinase)-
dependent pathway. PI-3 kinase activation required
a putative Src-homology domain (SH2) binding motif
in the MyD88 Toll-Like or IL-1 Receptor (TIR) domain.
Reconstitution of MyD88-deficient primary T cells
with a MyD88 transgene mutated in this motif abro-
gated association of PI-3 kinase with MyD88, phos-
phorylation of protein kinase B (Akt) and Glycogen
Synthetase Kinase-3 (GSK-3), and interleukin-2 (IL-2)
production. The MyD88 death domain, on the other
hand, was required for NF-kB activation and survival.
These studies identify a MyD88-dependent PI-3 ki-
nase-signaling pathway in T cells that differentiates
CpG DNA-mediated proliferation from survival and
is required for an in vivo T cell-dependent immune
response.
Introduction
Toll-like receptors (TLRs) are a major class of pattern
recognition receptors that facilitate discrimination of
self from nonself by the innate immune system (Medzhi-
tov and Janeway, 2002). The engagement of these re-
ceptors on antigen-presenting cells (APCs) controls
adaptive immune responses through the stimulation of
antigen presentation, upregulation of costimulatory li-
gands, and secretion of polarizing cytokines (Pasare
and Medzhitov, 2005). However, the recognition that T
cells express TLRs (Zarember and Godowski, 2002) sug-
gested to us that TLR agonists might directly control
functional responses of CD4+ T cells in an APC-indepen-
dent manner. Consistent with this, ligands for TLR2, 5, 8,
and 9 have all been shown to directly promote prolifera-
tive responses of CD3 mAb-stimulated CD4+ T cells
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School of Medicine, St. Louis, Missouri 63110.(Bendigs et al., 1999; Caron et al., 2005; Peng et al.,
2005). Similarly, interferon-g, interleukin-10 (IL-10), and
IL-8 secretion are enhanced by direct treatment of hu-
man CD3 mAb-stimulated CD4+ T cells with flagellin,
the ligand for TLR5, or R-848, a TLR7 or TLR8 agonist
(Crellin et al., 2005). Additionally, TLR4 expression in
mouse regulatory CD25+ CD4+ T cells has been linked
to lipopolysaccharide (LPS)-mediated enhancement of
their suppressive activity (Caramalho et al., 2003).
Despite the identification of APC-independent TLR
agonist-mediated effects on CD4+ T cells, little is known
about the intracellular pathways that mediate these
functional responses. TLR-signaling pathways have
been studied extensively in the context of APC function.
All TLRs, except TLR3, mediate signals through a path-
way via the toll-like or IL-1 receptor (TIR) domain con-
taining adaptor molecule MyD88 (O’Neill, 2006). The
functional responses from TLR2, 5, 7, 8, 9, and 11 in
APCs are completely dependent on the MyD88 pathway,
as is TLR-mediated secretion of inflammatory cytokines
by dendritic cells (DCs) (Akira et al., 2003). MyD88 medi-
ates TLR signaling through two critical domains. The
MyD88 N-terminal TIR domain recruits MyD88 to the TLR
after engagement, and the MyD88 death domain cou-
ples TLR:MyD88 association to the activation of down-
stream targets associated with inflammation, such as
nuclear factor kappa-B (NF-kB), mitogen-activated pro-
tein kinase (MAPK) p38, extracellular regulated kinase
(ERK) 1/2, and Janus kinases (Dunne and O’Neill, 2005).
Recently, it has been shown that TLR agonists acti-
vate Akt, a primary target of Phosphatidylinositol 3-ki-
nase (PI-3 kinase). The selective inhibition of PI-3 kinase
function in TLR2, 4, and 5 agonist-treated macrophages
leads to the enhancement of inflammatory responses.
This suggests that PI-3 kinase-signaling pathways neg-
atively regulate TLR function in APCs (Fukao et al., 2002;
Martin et al., 2005). In LPS-treated macrophages, PI-3
kinase activity and the regulatory subunit of PI-3 kinase
p85 have been reported to coprecipitate with MyD88
(Ojaniemi et al., 2003). However, it is unclear how or
whether MyD88 mediates PI-3 kinase activation.
In contrast to APCs, T cells employ PI-3 kinase-signal-
ing pathways to promote inflammatory responses such
as IL-2 synthesis, proliferation, and survival (Okkenhaug
et al., 2004). The use of PI-3 kinase-specific inhibitors
and the ectopic expression of a constitutively active
form of Akt, the primary target of PI-3 kinase, have
both shown that PI-3 kinase signaling is necessary in
CD4+ T cells for proliferative responses mediated by
CD28 stimulation (Kane et al., 2001; Ueda et al., 1995).
Additionally, CD28 promotes NF-kB activation, which
has also been shown to be required for optimal IL-2 syn-
thesis (Coudronniere et al., 2000). Thus, PI-3 kinase and
NF-kB activation are necessary to mediate CD28-medi-
ated proliferative responses in CD4+ T cells.
However, unlike CD28-signaling pathways, very little
is known about TLR agonist-mediated signaling in
CD4+ T cells. We previously reported expression of
TLR9 message on activated CD4+ T cells that was com-
parable to that of splenocytes (Gelman et al., 2004). In
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784Figure 1. CpG DNA Directly Promotes CD4+ T Cell Proliferation in a MyD88-Dependent Manner
(A) Purified Myd882/2 or wild-type littermate control CD4+ T cells were stimulated with graded concentrations of CD3 mAb in the presence of
irradiated T cell-depleted Myd882/2 splenocytes. Cultures were performed in the absence (open squares) or presence (closed squares) of
3.0 mM CpG ODN. Additionally, irradiated T cell-depleted Myd882/2 splenocytes were also first pretreated for 8 hr with 3 mM CpG ODN and
then washed 3 times prior to culture (open circles). After 72 hr, cultures were pulsed with [3H]thymidine and then harvested 16 hr later. Results
are indicated as mean 6 SD and are representative of two independent experiments.
(B) Purified Myd882/2 or wild-type (WT) littermate control CFSE-labeled CD4+ T cells were cultured with plate-bound CD3 mAb (0.3 mg/ml) in the
absence or presence of CpG DNA (3.0 mM), LPS (100 ng/ml), or CD28 mAb (1 mg/ml) for 72 hr. Proliferation was assessed by FACS analysis and is
represented by responder frequency (inset). Results are representative of five experiments.
(C) CD4+ T cells were purified by FACS, labeled with CFSE, and stimulated with plate-bound CD3 mAb at a limiting concentration of 0.3 mg/ml.
CpG ODN (1668), GpC ODN (1720), or a nonstimulatory ODN (AP1) were added to the cultures at varying concentrations as shown. LPS
(100 ng/ml) was used as a negative control and to assess the purity of the preparation, because CD4+ T cells are not directly stimulated by
LPS but receive costimulatory signals from LPS-activated APCs. Cells were cultured for 72 hr and harvested, and flow cytometry was performed
to assess proliferation by CFSE dilution and viability by 7-AAD exclusion. The number above each inset represents the percentage of live CD4+
T cells that responded to stimulation by dividing (responder frequency). One experiment representative of three is shown.that study, we additionally found that CpG DNA en-
hances survival in activated CD4+ T cells, an effect that
is MyD88 dependent and requires NF-kB activation.
Here we show that CpG DNA-driven costimulatory re-
sponses in CD4+ T cells is mediated through a MyD88-
dependent PI-3 kinase-signaling pathway. Stimulation
of CD4+ T cells with CD3 mAb in the presence of CpG
DNA induced an association of the p85 regulatory sub-
unit of PI-3 kinase with MyD88, as well as phosphoryla-
tion of Akt and glycogen synthetase kinase-3 (GSK-3).
Moreover, MyD88-dependent PI-3 kinase activation was
dependent on a single tyrosine residue, Y257, located in
a putative SH2 YKAM binding motif in the TIR domain.
The MyD88 death domain participated in optimal CpG
DNA-driven IL-2 production and proliferation, but it was
solely required for NF-kB activation, B cell lymphoma or
leukemia-xL protein (Bcl-xL) induction, and survival re-sponses that were all completely independent of Y257
and PI-3 kinase activation. Thus, specific outcomes of
CpG DNA stimulation of CD4+ T cells can be mapped
to discrete MyD88 motifs and MyD88-activated signal-
ing pathways.
Results
MyD88 in CD4+ T Cells Mediates Proliferative
Responses to CpG DNA
Previous studies have demonstrated that CpG DNA can
directly promote proliferative responses in T cells
(Bendigs et al., 1999; Mannon et al., 2000). Since the
TLR adaptor molecule MyD88 mediates functional re-
sponses to CpG DNA in APCs, we asked whether MyD88
is required for CpG DNA-driven proliferation in CD4+
T cells (Figure 1A). Purified Myd882/2 and wild-type
MyD88 Activates PI-3 Kinase in CD4+ T Cells
785CD4+ T cells were stimulated with irradiated Myd882/2
APCs and graded amounts of soluble CD3 mAb, and
proliferation was measured by thymidine incorporation
after 72 hr. CpG DNA enhanced wild-type CD4+ T cell
proliferation relative to cultures in media alone, an effect
that was most pronounced at suboptimal concentrations
of CD3. By contrast, Myd882/2 CD4+ T cells failed to re-
spond to CpG DNA irrespective of CD3 mAb concentra-
tion. As a means to assess the possibility that CpG DNA
was also acting on APCs to promote CD4+ T cell prolifer-
ation, we cultured wild-type or Myd882/2 CD4+ T cells
with Myd882/2 APCs that were first pretreated for 8 hr
with CpG DNA and then washed three times before
addition to cultures. These CpG DNA-pretreated APCs
failed to promote additional proliferation, indicating
that CpG DNA does not activate the Myd882/2 APCs in
our system.
We also measured proliferative responses by CSFE
dilution in order to assess the impact of MyD88 on the
frequency of CD4+ T cells that are recruited into the mi-
totic pool (Figure 1B). We observed that CpG DNA dou-
bled the responder frequency of CD4+ T cells, an effect
as potent as plate-bound CD28 mAb. However, CpG
DNA did not augment the responder frequency of
Myd882/2 CD4+ T cells. LPS, which induces the upregu-
lation of the CD28 ligands CD80 and CD86 on APCs in
a Myd88-independent manner, also failed to augment
proliferation in both wild-type and Myd882/2 CD4+ T
cells, indicating the functional absence of contaminating
APCs. Thus, the data taken collectively demonstrate
that MyD88 is required for the comitogenic effects of
CpG DNA in CD4+ T cells.
Because APCs are very sensitive to the effects of CpG
DNA and only small numbers of APCs are necessary to
provide T cell costimulation, it was important to rigor-
ously exclude the possibility that APCs contaminating
our T cell preparations might be responsible for CpG-
mediated T cell costimulation. In the experiments above,
CD4+ T cells were purified by Miltenyi columns and were
>96% pure. Importantly, all the contaminating cells were
CD8+ T cells, with no detectable APCs based on CD11c
staining (data not shown), nor detectable I-A transcripts
by RT-PCR (limit of detection 0.1% contamination; see
Figure S1 in the Supplemental Data available online).
Nonetheless, to verify our findings, we prepared FACS-
purified CD4+ T cells to greater than 99% purity and less
than 0.12% CD11c+ contamination (Figure S2) and stim-
ulated them with plate-bound CD3 plus graded concen-
trations of a stimulatory CpG oligodeoxynucleotide
(ODN), an inverted GpC ODN, or a known nonstimulatory
CpG ODN. LPS (100 ng/ml) was used as a negative con-
trol and to further verify the purity of the T cell population,
because CD4+ T cells are not directly stimulated by LPS
but receive costimulatory signals from LPS-activated
APCs. As shown in Figure 1C, the known stimulatory
CpG ODN, but not the control ODNs, provided a dose-
dependent comitogenic signal for highly purified CD3
mAb-stimulated T cells. Small responses to the control
ODNs were seen only at the highest concentration (con-
sistent with previous findings) and suggest that a propor-
tion of these responses may be sequence nonspecific.
To exclude the possibility that these stimulatory ef-
fects were due solely to the phosphorothioate backbone
of the modified CpG ODN (PS-ODN), we also tested theability of native phosphodiester CpG (PO-CpG) to costi-
mulate T cells. Since phosphodiester ODNs undergo
rapid nuclease-mediated degradation, weused liposome
encapsulation (Figure S3). We observed that PO-CpG
was almost as effective at promoting CD4+ T cell prolif-
eration as was PS-CpG, indicating that CD4+ T cells are
capable of responding to native phosphodiester CpG
DNA. Taken together, these data indicate that CpG
DNA can directly promote CD4+ T cell proliferation
responses without costimulatory signals from APCs.
CpG DNA-Mediated IL-2 Synthesis Is Both MyD88
and PI-3 Kinase Activation Dependent
Consistent with its ability to promote T cell proliferation,
CpG DNA synergized with CD3 to augment IL-2 produc-
tion in wild-type but not Myd882/2 CD4+ T cells
(Figure 2A). CD28-mediated IL-2 synthesis in T cells is
PI-3 kinase dependent, so we asked whether PI-3 kinase
had a role in CpG DNA-mediated IL-2 proliferation. CD4+
T cells were stimulated with plate-bound CD3 mAb with
or without CpG DNA, plate-bound CD28 mAbs, and the
pharmacological inhibitor of PI-3 kinase LY294002. CpG
DNA enhanced IL-2 synthesis in wild-type CD4+ T cells
to amounts comparable to those induced by CD28 cos-
timulation (Figure 2A). As with CD28 costimulation, PI-3
Figure 2. CpG DNA Promotes IL-2 Synthesis and Blocks Anergy In-
duction in a MyD88-Dependent Manner
(A) Purified Myd882/2 or wild-type control CD4+ T cells were acti-
vated with plate-bound CD3 (2.5 mg/ml) in the absence or presence
of listed combinations of CpG DNA (3.0 mM), Ly294002 (10 mM), or
plate-bound CD28 (2.5 mg/ml). IL-2 amounts were determined by
ELISA. Results are indicated as mean 6 SD and are representative
of three independent experiments.
(B) Purified Myd882/2 or wild-type CD4+ T cells were stimulated with
plate-bound CD3 mAb (2.5 mg/ml) in the presence or absence of ei-
ther CpG DNA (3.0 mM) or CD28 mAb for 24 hr, washed, rested for
48 hr, and restimulated with plate-bound CD3 and CD28 mAb
(2.5 mg/ml each) for additional 18 hr, and supernatant was assessed
for IL-2 by ELISA. Results are indicated as mean 6 SD and are rep-
resentative of three independent experiments.
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(A) Purified CD4+ T cells were activated with polystyrene beads coated with CD3 mAb (1 mg/ml) in the presence or absence of listed combinations
of CpG DNA (3.3 mM), Ly294002 (10 mM), or CD28 mAb-coated polystyrene beads (1 mg/ml) for 30 min. Cells were then lysed and analyzed by
immunoblot with antibodies specific for p-Akt or Akt. The result is representative of three experiments.
(B) Purified Myd882/2 or wild-type control littermate CD4+ T cells were activated with polystyrene beads coated with CD3 mAb (1 mg/ml) in the
presence or absence of CpG DNA (3.3 mM), CD28 mAb-coated polystyrene beads (1 mg/ml), or both for 30 min. Cells were then lysed and analyzed
by immunoblot with antibodies specific for p-Akt, p-GSK-3b, or actin. The result is representative of three experiments.
(C) Purified CD4+ T cells were stimulated with CD3 mAb (1.0 mg/ml)-coated beads in the presence or absence of 10 mM CpG DNA for 0, 30, or
60 min. Cells were then lysed and immunoprecipitated with rabbit antibodies specific for MyD88 and analyzed by immunoblot with antibodies
specific for p85 (top) and goat antibodies specific for MyD88 (bottom). Results are representative of two experiments.kinase inhibition completely abrogated CpG DNA-
mediated IL-2 synthesis.
To assess the significance of CpG DNA-mediated IL-2
synthesis, we also asked whether CpG DNA could
prevent anergy induction in CD4+ T cells (Figure 2B).
Wild-type or Myd882/2 CD4+ T cells were stimulated
with plate-bound CD3 mAbs in the presence or absence
of either CpG DNA or plate-bound CD28 mAb for 48 hr,
rested, and then restimulated with plate-bound CD3
and CD28 mAbs for 18 hr for assessment of IL-2 produc-
tion. We found that CpG DNA prevented anergy as mea-
sured by IL-2 synthesis in wild-type CD4+ T cells as ef-
fectively as did CD28 stimulation. Moreover, unlike the
situation for CD28 costimulation, CpG DNA prevention
of anergy was MyD88 dependent.
CpG DNA Stimulates MyD88 Association with p85
A primary target of the PI-3 kinase pathway is the serine-
threonine kinase Akt. Akt activation in turn augments
IL-2 gene expression through deactivating glycogen
synthetase kinases-3a or b (GSK-3a or b) to promote nu-
clear retention of the IL-2 transcription factor nuclear
factor of activated T cells (Beals et al., 1997). We asked
whether CpG DNA activated the Akt-GSK-3-signaling
pathway in CD4+ T cells. Purified wild-type CD4+ T cells
were stimulated with CD3 mAb-coated beads in the
presence or absence of combinations of CpG DNA,
LY294002, and CD28 mAb-coated beads (Figure 3A).
Lysates were immunoblotted and probed with phos-
pho-specific antibodies specific for Akt and GSK-3b.
We observed that CpG DNA and CD28 each markedly in-
creased Akt and GSK-3b phosphorylation compared to
CD3 mAb stimulation alone. LY294002 addition pre-
vented CpG DNA-mediated Akt and GSK-3b phosphor-
ylation, demonstrating that induction of this signaling
pathway is mediated through PI-3 kinase activation. Incontrast to wild-type CD4+ T cells, CpG DNA treatment
of CD3 mAb-stimulated Myd882/2 CD4+ T cells failed
to enhance either Akt or GSK-3b phosphorylation
(Figure 3B). However, CD28 ligation comparably pro-
moted Akt and GSK-3b phosphorylation in wild-type
and Myd882/2 CD4+ T cells, indicating that the absence
of CpG DNA-mediated Akt signaling is not the result of
an intrinsic defect in Myd882/2 CD4+ T cells.
We next asked whether MyD88 associated with p85
(the regulatory subunit of PI-3 kinase) in CpG DNA-
treated CD3-stimulated CD4+ T cells. Purified CD4+
T cells were stimulated with CD3 mAb in the presence or
absence of CpG DNA and then lysed. MyD88-p85 com-
plexes were immunoprecipitated with MyD88 anti-
bodies and then probed with p85-specific antibodies by
immunoblot. With this technique, we detected associa-
tion of p85 with MyD88 30 min after stimulation (Fig-
ure 3C). Moreover, p85-MyD88 complex formation was
dependent on CpG DNA treatment, since a p85 signal
was not detected in CD4+ T cells stimulated with only CD3
mAbs. Therefore,ourdata takencollectively demonstrate
that CpG DNA induces formation of complexes between
p85 and MyD88 and activates PI-3 kinase leading to
phosphorylation of the downstream targets Akt and GSK.
Y257 Is Required for p85 Association with MyD88
and Akt Activation
Alignment of MyD88 TIR domains of several vertebrate
species reveal a highly phylogenetically conserved pu-
tative YKXM SH2 binding motif (Figure 4A), representing
a potential binding sequence for p85. To address this is-
sue, lethally irradiated C57BL/6 mice were reconstituted
with Myd882/2 bone marrow that was transduced with
bicistronic retroviral vectors encoding a nonfunctional
form of the nerve growth factor receptor (NGFR) alone
or with either wild-type MyD88 or MyD88 with a Y257
MyD88 Activates PI-3 Kinase in CD4+ T Cells
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(A) Alignment of the MyD88 TIR domains of human, mouse, and zebrafish. The consensus YKXM motif is denoted with a large box, and boxed
amino acids denote differences between mouse with human or mouse with zebrafish.
(B) Myd882/2 mice were lethally irradiated and reconstituted with syngeneic Myd882/2 bone marrow that had been retrovirally transduced with
wild-type or mutant MyD88 constructs (mutation of Y/F mutation of Y257, truncated MyD88 TIR domain only, or both, as per Experimental Pro-
cedures). 3 months after reconstitution, purified NGFR+ CD4+ T cells were lysed and immunoblotted and probed with MyD88-specific antibodies.
(C) Purified CD4+ T cells from chimeras as described in (B) were stimulated with CD3 mAb (1.0 mg/ml)-coated beads in the presence or absence of
10 mM CpG DNA for 0, 30, or 60 min. Cells were then lysed and immunoprecipitated with rabbit antibodies specific for MyD88 and analyzed by
immunoblot with antibodies specific for p85 and goat antibodies specific for MyD88. Results are representative of two experiments.
(D) Purified CD4+ T cells as in (B) were activated with polystyrene beads coated with CD3 mAb (1 mg/ml) in the presence or absence of listed
combinations of CpG DNA (3.3 mM), Ly294002 (10 mM), or CD28 mAb-coated polystyrene beads (1 mg/ml) for 30 min. CD4+ T cells were then lysed
and analyzed by immunoblot with antibodies specific for p-Akt or Akt. The result is representative of two experiments.to F257 mutation (MyD88Y257F). Three months after re-
constitution, animals were sacrificed and CD4+ T cells
purified on the basis of NGFR expression. These cells
were lysed and assessed for expression of the trans-
gene protein with MyD88-specific antibodies (Figure 4B).
This demonstrated that amounts of the various MyD88
transgene-encoded proteins from radiation chimeras
were comparable to each other and to MyD88 protein
amounts in wild-type CD4+ T cells.
Next, NGFR+ CD4+ T cells were stimulated with plate-
bound CD3 mAb in the presence of CpG DNA, and the
cellular lysates were studied for coimmunoprecipitation
of MyD88 and p85 (Figure 4C). As previously observed in
wild-type CD4+ T cells, MyD88-p85 complexes were
readily observable in CD4+ T cells from Myd882/2 mice
reconstituted with a wild-type MyD88 transgene. How-
ever, mutation of the Y257 residue in the putative SH2
binding domain of MyD88 abolished complex formation,
demonstrating that Y257 is required for p85 association
with MyD88. Additional studies found that CpG DNA in-
creased Akt phosphorylation in CD4+ T cells expressing
MyD88 but not in CD4+ T cells expressing either NGFR
alone or MyD88 Y257F, demonstrating that PI-3 kinase
activation by CpG DNA is dependent on the presence
of Y257 (Figure 4D). Thus, our data indicate the presence
of a MyD88 SH2 binding motif in the TIR domain that
functions to promote CpG DNA-mediated PI-3 kinase
recruitment and activation in CD4+ T cells.
Proliferative Responses Require Both the MyD88
Death Domain and Y257
Although the data above indicate that MyD88, via its TIR
domain, can activate PI-3 kinase, activation of NF-kB viathe MyD88 death domain could also play a role in CD4+ T
cell proliferative responses. To test this, additional
MyD88 constructs were used for retroviral reconstitu-
tion of Myd882/2 mice. These were a MyD88 construct
lacking the death domain (MyD88 TIR) and MyD88 TIR
containing the mutated SH2 binding domain (MyD88
TIR Y257F) (Figure 5). We observed that mutation of
Y257 alone dramatically reduced the ability of CpG
DNA to synergize with suboptimal concentrations of
CD3 mAb to induce proliferation and completely abol-
ished the ability of CpG DNA to augment proliferation
in response to high CD3 concentrations (Figures 5A
and 5B). CD4+ T cells lacking the death domain of
MyD88 (i.e., MyD88 TIR and MyD88 TIR Y257F) did not
respond to CpG DNA treatment (as assessed by prolifer-
ation) irrespective of CD3 mAb concentration.
Similar effects were seen on CpG DNA-mediated
enhancement of IL-2 production (Figure 5C). IL-2
concentrations from MyD88Y257F CD4+ T cells were
approximately a third of that from MyD88 CD4+ T cells.
Nevertheless, MyD88Y257F CD4+ T cells responded
normally to CD28 stimulation, indicating that they have
no intrinsic defect in IL-2 synthesis. As predicted based
on experiments above, LY294002 treatment inhibited
CpG DNA-mediated IL-2 synthesis in both MyD88 and
MyD88Y257F CD4+ T cells. Moreover, TIR and TIRY257F
CD4+ T cells were completely unresponsive to CpG DNA
treatment. Therefore, the data taken collectively show
that the MyD88 TIR Y257 signal is required for activation
of PI-3 kinase via MyD88 but that this must combine with
signals derived from the MyD88 death domain to drive
optimal CpG DNA-mediated IL-2 and proliferative sig-
nals in CD4+ T cells.
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(A) Purified NGFR+ CD4+ T cells coexpressing MyD88, MyD88 Y257, MyD88 TIR, or MyD88 TIRY257F transgenes isolated from radiation bone
chimeras were stimulated with graded concentrations of CD3 mAb in the presence of irradiated T cell-depleted Myd882/2 splenocytes. Cultures
were performed in the absence (open squares) or presence (closed squares) of 3.0 mM CpG ODN. Additionally, irradiated T cell-depleted
Myd882/2 splenocytes were first pretreated for 8 hr with 3 mM CpG ODN and then washed three times prior to culture (open circles). After
72 hr, cultures were pulsed with 3H thymidine and then harvested 16 hr later. Results are indicated as mean 6 SD and are representative of
two experiments.
(B) CSFE-labeled CD4+ T cells prepared as in (A) were cultured with plate-bound CD3 mAb (0.3 mg/ml) in the absence or presence of CpG ODN
(3.0 mM) or CD28 (1 mg/ml) for 72 hr and then analyzed by FACS. Proliferation is represented by percent CSFE dilution (inset). Results are rep-
resentative of two experiments.
(C) Purified CD4+ T cells prepared as in (A) were activated with plate-bound CD3 (2.5 mg/ml) alone (open bars) or in the presence of either 3.0 mM
CpG DNA (closed bars), 3.0mM CpG DNA and Ly2924002 (horizontal striped bars), or 2.5mg/ml of plate-bound CD28 (vertical striped bars) for 18 hr.
IL-2 amounts were determined by bead ELISA. Results are indicated as a mean 6 SD and are representative of two independent experiments.MyD88 Death Domain but Not Y257 Is Required
for Survival Signals
We next tested the relative role of MyD88 PI-3 kinase
and death domain-derived signals in the ability of CpG
DNA to promote T cell survival. Purified MyD88, My-
D88Y257F, TIR, TIR257F, or NGFR only expressing
CD4+ T cells were activated with plate-bound CD3mAbs + CD28 mAbs for 8 hr, washed, and recultured
with or without CpG DNA or Poly I:C. Cells were har-
vested 72 hr later, and activated CD4+ T cell survival
was measured by annexin stain and live cell count (Fig-
ure 6A). CpG DNA enhanced cell survival, measured by
an absolute increase in annexin-negative cells, by more
than 30% in both MyD88 and MyD88Y257F CD4+ T cell
MyD88 Activates PI-3 Kinase in CD4+ T Cells
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Upregulation
(A) Purified NGFR+ CD4+ T cells coexpressing MyD88, MyD88 Y257F, MyD88 TIR, or MyD88 TIRY257F transgenes isolated from bone marrow
chimeras were activated with plate-bound CD3 mAb (0.3 mg/ml) + CD28 mAbs (2.5 mg/ml) for 16 hr, washed, and then recultured in quadruplicate
wells at 500,000 cells/well alone (open bars) or in the presence of either 10 mM CpG DNA (closed bars) or 30 mg/ml of poly I:C (shaded bars) for an
additional 72 hr. Cells were then either assessed for viability by the exclusion of annexin staining (top) or live cell counts (bottom). Results are
indicated as a mean 6 SD and are representative of two independent experiments.
(B) Purified NGFR+ CD4+ T cells coexpressing MyD88, MyD88 Y257, or MyD88 TIR transgenes isolated from bone marrow chimeras were acti-
vated with plate-bound CD3 mAb (2.5 mg/ml) + CD28 mAbs (2.5 mg/ml) for 8 hr, washed, rested for 24 hr, treated with 10 mM CpG DNA for indicated
periods, lysed, and analyzed by immunoblot with antibodies specific for p-IkBa and total IkBa.
(C) Purified NGFR+ CD4+ T cells prepared as in (B) were activated with plate-bound CD3 mAb (2.5 mg/ml) in the presence or absence of CD28 mAb
(2.5 mg/ml) or CpG ODN (3.0 mM) for 48 hr, lysed, and probed by immunoblot with antibodies specific for Bcl-xL and b-actin.cultures and had similar effects on live cell numbers. By
contrast, CpG DNA did not promote survival of TIR,
TIRY257F, or NGFR CD4+ T cells. However, Poly I:C,
which we have previously shown to enhance the survival
of activated CD4+ T cells in a MyD88-independent
manner (Gelman et al., 2004), was able to increase the
survival of TIR, TIRY257F, or NGFR CD4+ T cells to a
comparable degree, indicating that there is no intrinsic
defect of survival responses.
The ability of CpG DNA to promote survival in acti-
vated T cells expressing MyD88 or MyD88 Y257F was
associated with IkBa phosphorylation and degradation
(Figure 6B) and Bcl-xL upregulation (Figure 6C), events
that failed to occur in cells reconstituted with MyD88
constructs lacking the death domain. The specificity of
this signaling defect is illustrated by the fact that CD4+
T TIR cells and NGFR+ CD4+ T cells were able to upregu-
late Bcl-xL in response to CD28 stimulation. Consistent
with the specific requirement of the death domain for
NF-kB activation, the PI-3kinase inhibitor LY294002
did not block CpG DNA-mediated IkB degradation
(Figure S4). Thus, CpG DNA-mediated survival occurs
in conjunction with NF-kB activation and Bcl-xL upregu-
lation and is dependent on MyD88 death domain
signals, but unlike CpG DNA-mediated proliferative re-
sponses, it is independent of Y257-mediated PI-3 kinase
signals.
T Cell Expression of MyD88 Is Required for IgG
Antibody Responses to a T Cell-Dependent
Antigen In Vivo
CD4+ T cell activation mediated by DC maturation to
TLR ligands has been shown to regulate B cell differen-
tiation to T cell-dependent antigens (Banchereau and
Steinman, 1998). However, it is not known whether di-
rect TLR ligand stimulation of CD4+ T cells also plays a
role in B cell responses. To address this, we reconsti-tuted SCID mice with wild-type B cells plus CD4+ T cells
that were obtained from wild-type, Myd882/2, or
Cd282/2 mice, or derived from bone marrow chimeras
made by transducing Myd882/2 bone marrow with
either wild-type MyD88, MyD88 Y257F, or MyD88 TIR.
We then immunized these mice with the T cell-depen-
dent antigen KLH in the presence or absence of CpG
DNA and assessed a primary IgG response 21 days after
immunization (Figure 7). We found markedly reduced
anti-KLH IgG titers in SCID mice containing MyD88-
deficient (or CD28-deficient) CD4+ T cells compared to
SCID mice bearing wild-type CD4+ T cells. Moreover,
SCID mice bearing the mutated MyD88Y257F CD4+ T
cells or MyD88 TIR CD4+ T cells had similar anti-KLH
IgG titers to SCID mice bearing CD28-deficient CD4+ T
cells, indicating that CpG DNA-mediated PI-3 kinase ac-
tivation via T cell-expressed MyD88 can regulate a CD4+
T cell-dependent response in vivo.
Discussion
MyD88 is the most proximal part of a common TLR
signaling pathway that promotes inflammatory cytokine
responses in APCs. Here, we report that this pathway
mediates enhanced IL-2 production, proliferation, and
survival after CpG DNA stimulation of activated CD4+ T
cells. These downstream functional effects result from
the cooperative activation of the PI-3 kinase and
NF-kB pathways, with the former predominantly mediat-
ing IL-2 production and proliferation and the latter being
completely required for antiapoptotic effects.
The ability of MyD88 to activate NF-kB is well recog-
nized and is mediated via death domain homotypic in-
teractions of MyD88 and the interleukin 1 receptor-asso-
ciated kinases IRAK and IRAK-4, which promote TRAF 6
stimulation of the canonical IkB kinase pathway leading
to NF-kB activation. However, it is not clear how MyD88
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kinase activity has been described in two studies in
which TLR-mediated PI-3 kinase activation was found to
regulate inflammatory function in macrophages and co-
lonic epithelial cells (Ojaniemi et al., 2003; Rhee et al.,
2006). Nevertheless, in these studies the molecular
mechanism by which MyD88 might lead to PI-3 kinase
activation was not defined. Moreover, there has also
been a single report of CpG DNA-mediated Akt phos-
phorylation via the DNA protein-dependent kinase
DNA-PK in TLR9-deficient macrophages (Dragoi et al.,
2005). This would suggest that there is a PI-3 kinase-
and MyD88-independent pathway in CD4+ T cells that
mediates CpG DNA-induced Akt phosphorylation. How-
ever, we observed that Akt phosphorylation was MyD88
dependent and likely mediated through PI-3 kinase acti-
vation since this Akt phosphorylation required the asso-
ciation of the p85 regulatory subunit of PI-3 kinase with
MyD88.
The location of the binding motif for p85 in the MyD88
TIR domain is consistent with a model of PI-3 kinase ac-
tivation where access to its lipid substrate phosphatidy-
linositol-(4,5)-bisphosphate occurs after homodimeric
interaction between MyD88 TIR and TLR TIR domains
at the inner leaflet of a phospholipid bilayer. This result
also infers that the phosphorylation of Y257 is required
to initiate p85 association with MyD88. However, we
could not observe CpG DNA-induced changes in the
phosphorylation state of MyD88 because of high basal
tyrosine phosphorylation (data not shown). Neverthe-
less, our result is similar to several studies in which an
analogous mutation, introduced into known lymphocyte
receptor SH2-binding motifs, resulted in the loss of p85
association and Akt phosphorylation (Okkenhaug and
Vanhaesebroeck, 2003).
We also investigated whether CpG DNA-mediated
MyD88 signals in CD4+ T cells are functionally significant
in vivo. KLH-CpG DNA-immunized SCID mice bearing
eitherMyd882/2,MyD88Y257,orMyD88TIRCD4+ Tcells
Figure 7. Requirement for MyD88 on CD4+ T Cells for CpG DNA-Me-
diated Anti-IgG Responses to a T Cell-Dependent Antigen In Vivo
Wild-type B cells alone or with either wild-type, Cd282/2, Myd882/2,
NGFR only, MyD88 Y257, or MyD88 TIR CD4+ T cells were adoptively
transferred into SCID mice. After a 6 week rest, reconstituted SCID
mice were immunized with either 50 mg KLH in 200 ml PBS (open
squares) or 50 mg KLH and 4 mM CpG DNA in 200 ml PBS (closed cir-
cles), and serum was assessed at day 21 for anti-KLH IgG by ELISA.
Results are representative of two independent experiments.were defective in anti-KLH IgG responses relative to
KLH-CpG DNA-immunized SCID mice bearing wild-type
CD4+ T cells. These observations are consistent with
previous reports showing that CD28-deficient mice im-
munized with T cell-dependent antigens had poor anti-
KLH IgG responses in comparison to their wild-type
counterparts (Ferguson et al., 1996; Shahinian et al.,
1993). Thus, like CD28-mediated comitogenic signals,
MyD88-dependent PI-3 kinase and death domain signals
are both required to mediate T cell-dependent B cell re-
sponses. These observations have led us to note that the
comitogenic, anergy prevention, and prosurvival effects
of CpG DNA, along with its ability to activate PI-3 kinase,
are reminiscent of the effects of CD28 costimulation, and
indeed we observed a similar degree of ‘‘potency’’ when
the two types of stimuli were directly compared. We con-
sidered therefore that CpG DNA might act directly via the
CD28 receptor. However, we and others have found that
CpG DNA is as effective in Cd282/2 CD4+ T cells as in
wild-type T cells (Figure S5; Bendigs et al., 1999).
The precise mechanism by which critical PI-3 kinase
signals are generally initiated after TCR plus CD28 stim-
ulation of T cells remains under investigation. In our ex-
periments, we found that mutation of a single tyrosine
residue in a putative SH2 binding domain within
MyD88 abolished p85 association with MyD88 and abro-
gated PI-3 kinase activation. Interestingly, this model for
MyD88-mediated PI-3 kinase activation and prolifera-
tion is in contrast to results found in a mouse model
with a CD28 transgene with a targeted Y170F SH2 muta-
tion (Okkenhaug et al., 2001). In that report, the loss of
CD28-mediated recruitment of p85 was associated
with an absence of upregulated Akt phosphorylation,
but IL-2 synthesis and proliferation enhancement was
not affected. However, how CD28 mediates proliferative
signals remains unclear. Other studies have proposed
that CD28 proliferative signals are dependent on a set
of cytoplasmic carboxy-terminal diproline motifs in
CD28 that act by sustaining tyrosine kinase activity nec-
essary to promote TCR-mediated PI-3 kinase activation
(Burr et al., 2001; Holdorf et al., 1999; Marengere et al.,
1997; Okkenhaug and Vanhaesebroeck, 2003). Thus,
despite the apparent similarity in functional outcomes
of CD28 and CpG DNA stimulation, the mechanism
that generates the critical PI-3 kinase signals to promote
proliferation are likely to be qualitatively different.
As is the case with CD28 costimulation, signals other
than PI-3 kinase are also important for MyD88’s effects
on T cell activation, as shown by the fact that we found
that NF-kB activation via the MyD88 death domain is
required to synergize with Y257-mediated PI-3 kinase
activation for induction of proliferation and is solely
needed for induction of Bcl-xL upregulation and
survival. This does not imply, however, that the CpG
DNA-mediated activated CD4+ T cell survival is com-
pletely independent of PI-3 kinase: these signals may
be provided in trans by the T cell receptor and during
later points of activation and differentiation (Costello
et al., 2002; Exley and Varticovski, 1997; Reynolds
et al., 2002). The fact that the MyD88 death domain is re-
quired for both CpG DNA-mediated IL-2 production and
survival implies a critical role for NF-kB and is consistent
with the dependence of enhanced IL-2 and Bcl-xL gene
transcription on CD28-mediated nuclear translocation
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791of the NF-kB family members p65, p50, and c-Rel to the
CD28 response element (Chen et al., 2000; Coudron-
niere et al., 2000; Kontgen et al., 1995; Zheng et al.,
2003). Taken together, our data suggest a signaling
model of CpG DNA-mediated functional responses in
CD4+ T cells in which proliferation is dependent on the
coupling of PI-3 kinase signals generated by MyD88
Y257 to MyD88 death domain signals (Figure S6). Mutat-
ing Y257 effectively dissociates CpG DNA-mediated
proliferation from survival, which only requires MyD88
death domain signals that lead to NF-kB activation and
Bcl-xL upregulation. Recent studies suggest that mam-
malian DNA may act as an endogenous ligand for TLRs,
and our studies provide a mechanism whereby tissue
inflammation and necrosis may promote a positive feed-
back loop for the generation and maintenance of T cell
responses (Christensen et al., 2005).
Experimental Procedures
Reagents
All CD4+ T cell assays were conducted in complete culture medium
(CM) composed of RPMI 1640 (Life Technologies), 1.5 mM b-mercap-
toethanol (Sigma Biochemical), 50 mg/ml gentamicin (Life Technolo-
gies), and 10% fetal calf serum (Mediatech) at 37C in 5% CO2. The
oligodeoxynucleotides (ODN) used have previously been described
(Bendigs et al., 1999), and all were synthesized on a phosphoro-
thioate backbone and then purified by HPLC (Life Technologies).
The sequences are as follows: CpG DNA (1668), TCCATGACGT
TCCTGATGCT; the inverted GpC ODN (1720), TCCATGAGCTTCCT
GATGCT; and the nonstimulatory CpG ODN (AP1), GCTTGATGACT
CAGCCGGAA. The pMX vector and Plat E cells was a generous gift
from A. Kitamura. Poly I:C was purchased from Amersham Biosci-
ences, and LPS, derived from the O55:B5 E. coli strain, was pur-
chased from Sigma Biochemicals. CD33 mAb (2C11), CD45.1-PE
(37.51) mAb, CD28 mAb, CD4 mAb, biotinylated NGFR mAb, and
Annexin-FITC were purchased from BD-Pharmingen. Rabbit anti-
mouse MyD88 (raised against full-length mouse MyD88 protein:
FL-296) and goat anti-mouse MyD88 (raised against N-terminal pep-
tide: F-19) were both purchased from Santa Cruz Biotechnologies.
Unless otherwise indicated, antibodies used in immunoblot analysis
were purchased from Cell Signal Technologies except for anti-Bcl-
xL, anti-PI-3 kinase p85, and anti-b-Actin, which were all purchased
from Upstate Biotechnologies.
Mice
Myd882/2 mice were a generous gift from S. Akira. For these exper-
iments, Myd88+/2 mice were backcrossed at least five times onto
a C57BL/6 background and intercrossed to generate Myd882/2
and Myd88+/+ wild-type control littermates. SCID and CD282/2
mice on a C57BL/6 background were obtained from Jackson Labo-
ratories. Mice were housed under conventional barrier protection in
accordance with University of Pennsylvania and NIH guidelines, and
mouse protocols were approved by the University of Pennsylvania
Institutional Animal Care Committee.
Immunoblot and Immunoprecipitation Analysis
2–53 106 purified CD4+ T cells were lysed in 40 ml in SDS-PAGE/lysis
buffer (Bio Rad), resolved on a 12% Bis-Tris SDS-PAGE gel (Life
Technologies), transferred to nitrocellulose filters (Life Technolo-
gies), and probed with rabbit anti-mouse phospho-specific Abs for
p-Ikba, p-Akt, or p-GSK-3b. To assess total amounts of protein,
filters were also probed with antibodies specific for Ikba, Akt,
GSK-3, Bcl-xL, MyD88, PI-3 kinase p85, or b-actin. Detection was
conducted with HRP conjugated secondary Abs (Amersham), ECL
reagent (Amersham), and X-OMAT Film (Kodak). For immunoprecip-
itation of MyD88 complexes, 107 CD4+ T cells were lysed in digitonin
lysis buffer (1% Digitonin [Calbiochem], 50 mM Tris [pH 7.4], 100 mM
NaCl, 1 mM vanadate, 1 mM EDTA, 50 mM NaF, and 23 protease in-
hibitor cocktail [Roche Biochemical]) for 2 hr at 4C. Lysates were
cleared by centrifugation for 10 min at 16,000 3 g and incubatedovernight with goat anti-mouse MyD88 (F-19) and Protein A/G aga-
rose (Santa Cruz Biotechnologies) at 4C. Complexes were washed
33 in digitonin lysis buffer and resolved by a 12% Bis-Tris SDS-
PAGE (Invitrogen), transferred to nitrocellulose filters (Bio Rad),
and probed with either rabbit anti-mouse MyD88 (FL-296) or rab-
bit-anti PI-3 kinase p85 antibodies.
MyD88 Retroviral Vectors
MyD88 cDNA was generated from mRNA from C57BL/6 splenocytes
by reverse transcription with SuperScript III RT polymerase (Invitro-
gen) and PCR amplification with Pfu polymerase (Stratagene) and
subcloned into EcoRI site of the bicistronic retroviral vector pMX
NGFR (which expresses a nonfunctional form of the human nerve
growth factor). MyD88 TIR cDNA was generated with a primer with
a start codon place before AA (50-GGAATTCGCACATGGACCCCCT
AGGACAAACGC-30) and a primer that is specific for the 30 end of the
ORF of MyD88. The introduction of Y257F mutation of MyD88 and
MyD88 TIR was accomplished with a QuikChange site-directed mu-
tagenesis kit (Stratagene) and primers designed in accordance with
manufacturer’s recommendations (50-GATTCCTATTAAATTCAAGG
CGATGAAG-30 and 50-CTTCATCGCCTTGAATTTAATAGGAATC-30).
All transgeneMyD88cDNAswere sequenced andanalyzed by BLAST
with mouse MyD88 cDNA (NCBI:NM 010851). Transgene MyD88
cDNAs were sublconed into the EcoRI site of the bicistronic retroviral
vector pMX NGFR to create all indicated retroviral vectors. High-titer
pMX MyD88 NGFR retroviral supernatant was made with the previ-
ously described Plat E packaging cell line (Morita et al., 2000). Plat
E cells were transfected with 5 mg of indicated pMX NGFR MyD88
plasmids or 5 mg of pMX NGFR plasmid (no transgene) complexed
to 293 Transit lipofectin (Mirus). Cultures were incubated for 4 days
and then filtered through 0.2 mm acrodisc (Nalgene) and assessed
for titer in NIH 3T3 cells as previously described (Kitamura, 1998).
Sequence Alignment
Human (NCBI:AK 124685), mouse (NCBI:NM 010851), and zebrafish
(NCBI:NM 212814) MyD88 cDNA sequences were aligned with
Lasergene MegAlign (DNASTAR) software.
Bone Marrow Chimeras and CD4+ T Cell Purification
Bone marrow suspensions were prepared from 6-week-old female
Myd882/2 mice, transduced with normalized high-titer pMX
MyD88 NGFR constructs, and injected into lethally irradiated
(1000R) wild-type littermate mice by a previously described method
(Pui et al., 1999). Recipients were allowed to reconstitute for
3 months, then were sacrificed and CD4+ T cells were purified by
negative selection from erythrocyte-depleted splenocyte and lymph
node cells via MACS CD4+ T cell isolation kits and LS columns (Mil-
tenyi Biotec) in accordance with the manufacturer’s recommenda-
tions. Purity of these CD4+ T cells exceeded 96%. The remainder
of the cells were CD8+ T cells (data not shown). To isolate NGFR+
CD4+ T cell fraction, purified CD4+ T cells were further incubated
with biotinylated NGFR Abs, anti-biotin magnetic beads (Miltenyi
Biotec) and positively selected on LS columns (Miltenyi Biotec) in
accordance with the manufacturer’s recommendations.
CD4+ T Cell IL-2 and Proliferation
Purified CD4+ T cells were activated with plate-bound CD3
(2.5 mg/ml) in the presence or absence of CD28 (2.5 mg/ml), 5 mM
LY294002 (Calbiochem), or 3 mM CpG DNA in triplicate in 96-well
plates. Supernatant after 18 hr was assessed for IL-2 amounts by
bead ELISA (BD Pharmingen). For proliferation measurements em-
ploying plate-bound antibody stimulation, purified CD4+ T cells
were labeled with 5-(and-6)-carboxyfluorescein diacetate, succini-
midyl ester (CFSE) dye (Molecular Probes) as previously described
(Wells et al., 1997). Then, CD4+ T cells were activated on 96-well
plates (Costar) coated with 0.3 mg/ml CD33 mAb with or without
CpG DNA, LPS, or 2.5 mg/ml CD28 mAb for 72 hr and assessed for
CSFE dye dilution by FACS analysis. For soluble CD3 mAb + spleno-
cyte stimulation, 150,000 irradiated (2500R) T cell-depleted
Myd882/2 splenocytes, 150,000 purified CD4+ T cells, and indicated
concentrations of CD3 mAb in the presence or absence of 3 mM CpG
DNA were cultured in 96-well plates (Costar). In a cohort of cultures
that did not receive direct CpG DNA treatment of CD4+ T cells,
Myd882/2 splenocytes were precultured with 3 mM of CpG DNA for
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sible MyD88-independent effects of the CpG DNA reagent on spleno-
cytes. After 72 hr of culture, 1 mCi of [3H]thymidine (Amersham) was
added to each well for an additional 16 hr and counts were read on
a Cell Harvester and scintillation counter (Molecular Devices) and is
expressed as a mean for each treatment group 6 SEM.
Activated CD4+ T Cell Survival
2.5 3 106 CD4+ T cells were activated on 24-well plates (Costar)
coated with 0.3 mg/ml CD3 and 2.5 mg/ml CD28 mAbs for 16 hr, frac-
tionated over a Ficoll (Sigma) opaque gradient to remove dead cells,
washed 23, and recultured in 500,000 per well in quadruplicate for
72 hr in the presence or absence of 10 mM CpG DNA or 30 mg/ml
Poly I:C for 72 hr. After incubation, CD4+ T cells were washed twice
and stained with CD4-APC mAb and Annexin-FITC and survival was
assessed by percentage of exclusion of Annexin. For live CD4+ T cell
counts, 500,000 CD45.1+ splenocytes labeled with CD45.1-PE mAb
was also added to CD4-APC/Annexin-FITC-stained samples. Live
CD4+ T cell counts were calculated, taking the ratio of the number
of CD4+ CD45.12 Annexin2 events collected to the number
CD45.1+ events collected and multiplying by 500,000.
SCID Mice Reconstitution and Anti-KLH IgG Responses
107 wild-type B cells alone or with either 53 106 wild-type, Cd282/2,
Myd882/2, NGFR, MyD88, MyD88 Y257, or MyD88 TIR CD4+ T cells
were adoptively transferred into 6- to 8-week-old SCID mice. Six
weeks later, the reconstituted SCID mice were immunized with ei-
ther 50 mg Keyhole Limpet Hemocyanin (Sigma) carried with 200 ml
PBS or 50 mg KLH/0.8 nanomoles (4 mM) CpG DNA/200 ml PBS in
the right hind leg, and serum was drawn 21 days later. Serum
amounts of KLH-specific IgG were measured by ELISA. 96-well
ELISA plates (Costar) were coated with 10 mg/ml of KLH in carbonate
buffer (0.1 M NaHCO3 [pH 9.6]) for 2 hr and washed 33 with PBS
wash (PBS/0.05% Triton X-100). The plates were then blocked
with 3.5% nonfat dry milk and washed 53, and a 1:500 dilution of se-
rum in PBS + 2% BSA were added for 1 hr. Plates were then washed
73, probed with biotinylated goat anti-mouse (whole) IgG (Kirke-
gaard & Perry), washed 73, and developed with ABTS (Kirkegaard
& Perry) and read at 405 nm with a reference wavelength of 490 nm.
Supplemental Data
Six Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/5/783/DC1/.
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